Aimmune Therapeutics Inc (AIMT) Expected to Announce Earnings of -$0.92 Per Share

Analysts expect that Aimmune Therapeutics Inc (NASDAQ:AIMT) will post earnings per share of ($0.92) for the current quarter, Zacks reports. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.99) and the highest estimate coming in at ($0.79). Aimmune Therapeutics also posted earnings of ($0.92) per share during the same quarter last year. The firm is expected to issue its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Aimmune Therapeutics will report full-year earnings of ($3.85) per share for the current fiscal year, with EPS estimates ranging from ($4.39) to ($3.28). For the next financial year, analysts forecast that the firm will report earnings of ($2.73) per share, with EPS estimates ranging from ($3.52) to ($2.03). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that follow Aimmune Therapeutics.

AIMT has been the subject of several recent analyst reports. BidaskClub raised shares of Aimmune Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, February 4th. ValuEngine lowered shares of Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, January 14th. Credit Suisse Group restated a “buy” rating and issued a $40.00 price objective on shares of Aimmune Therapeutics in a report on Tuesday, January 15th. Finally, Cantor Fitzgerald set a $45.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Aimmune Therapeutics currently has an average rating of “Hold” and an average target price of $47.13.

Several large investors have recently added to or reduced their stakes in AIMT. Geode Capital Management LLC boosted its position in shares of Aimmune Therapeutics by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 472,225 shares of the biotechnology company’s stock valued at $11,295,000 after acquiring an additional 28,694 shares during the last quarter. Norges Bank bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $6,035,000. Legal & General Group Plc lifted its position in shares of Aimmune Therapeutics by 29.1% during the fourth quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock worth $437,000 after purchasing an additional 4,123 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $139,000. Finally, Opaleye Management Inc. bought a new stake in shares of Aimmune Therapeutics during the fourth quarter worth $3,588,000. 73.85% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AIMT traded up $0.24 during trading hours on Thursday, hitting $23.35. The company’s stock had a trading volume of 626,225 shares, compared to its average volume of 631,388. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -6.36 and a beta of -0.13. Aimmune Therapeutics has a 52-week low of $20.94 and a 52-week high of $36.12.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Story: Float

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.